BACKGROUND: Infant HIV-1 infection is associated with impaired neurologic and motor development. Antiretroviral therapy (ART) has the potential to improve developmental outcomes but the relative contributions of pre-ART disease status, growth, treatment regimen and ART response during infancy are unknown. METHODS: Kenyan ART-naive infants <5-months old initiated ART and had monthly assessment of age of full neck control, unsupported walking and monosyllabic speech during 24 months of follow-up. Pre-ART and post-ART correlates of age at milestone attainment were evaluated using t tests or multivariate linear regression. RESULTS: Among 99 infants, pre-ART correlates of later milestone attainment included: underweight and stunted (neck control, walking and speech, all P values <0.05), missed prevention of mother-to-child transmission (P = 0.04) (neck control), previous hospitalization, World Health Organization (WHO) Stage III/IV, low CD4 count, and wasting (speech and walking, all P values <0.05), and low maternal CD4 (speech, P = 0.04). Infants initiated ART at a median of 14 days following enrollment. Infants receiving nevirapinevs lopinavir/ritonavir-based ART attained later speech (18.1 vs. 15.5 months, P = 0.003) [corrected]. Adjusting for pre-ART level, lower 6-month gain in CD4% was associated with later walking (0.18 months earlier per unit increase in CD4%; P = 0.004) and speech (0.12 months earlier per unit increase in CD4%; P = 0.05), and lower 6-month gains in weight-for-age (P = 0.009), height-for-age (P = 0.03) and weight-for-height (P = 0.02) were associated with later walking. CONCLUSION: In HIV-infected infants, compromised pre-ART immune and growth status, poor post-ART immune and growth responses, and use of nevirapine- vs. lopinavir/ritonavir-based ART were each associated with later milestone attainment [corrected]. The long-term consequences of these delays are unknown.
RCT Entities:
BACKGROUND:InfantHIV-1 infection is associated with impaired neurologic and motor development. Antiretroviral therapy (ART) has the potential to improve developmental outcomes but the relative contributions of pre-ART disease status, growth, treatment regimen and ART response during infancy are unknown. METHODS: Kenyan ART-naive infants <5-months old initiated ART and had monthly assessment of age of full neck control, unsupported walking and monosyllabic speech during 24 months of follow-up. Pre-ART and post-ART correlates of age at milestone attainment were evaluated using t tests or multivariate linear regression. RESULTS: Among 99 infants, pre-ART correlates of later milestone attainment included: underweight and stunted (neck control, walking and speech, all P values <0.05), missed prevention of mother-to-child transmission (P = 0.04) (neck control), previous hospitalization, World Health Organization (WHO) Stage III/IV, low CD4 count, and wasting (speech and walking, all P values <0.05), and low maternal CD4 (speech, P = 0.04). Infants initiated ART at a median of 14 days following enrollment. Infants receiving nevirapinevslopinavir/ritonavir-based ART attained later speech (18.1 vs. 15.5 months, P = 0.003) [corrected]. Adjusting for pre-ART level, lower 6-month gain in CD4% was associated with later walking (0.18 months earlier per unit increase in CD4%; P = 0.004) and speech (0.12 months earlier per unit increase in CD4%; P = 0.05), and lower 6-month gains in weight-for-age (P = 0.009), height-for-age (P = 0.03) and weight-for-height (P = 0.02) were associated with later walking. CONCLUSION: In HIV-infectedinfants, compromised pre-ART immune and growth status, poor post-ART immune and growth responses, and use of nevirapine- vs. lopinavir/ritonavir-based ART were each associated with later milestone attainment [corrected]. The long-term consequences of these delays are unknown.
Authors: D Drotar; K Olness; M Wiznitzer; L Guay; L Marum; G Svilar; D Hom; J F Fagan; C Ndugwa; R Kiziri-Mayengo Journal: Pediatrics Date: 1997-07 Impact factor: 7.124
Authors: C DeCarli; L Fugate; J Falloon; J Eddy; D A Katz; R P Friedland; S I Rapoport; P Brouwers; P A Pizzo Journal: J Acquir Immune Defic Syndr (1988) Date: 1991
Authors: R Smith; K Malee; M Charurat; L Magder; C Mellins; C Macmillan; J Hittleman; T Lasky; A Llorente; J Moye Journal: Pediatr Infect Dis J Date: 2000-09 Impact factor: 2.129
Authors: Cynthia McCoig; Maria Mercedes Castrejón; Elizabeth Castaño; Onix De Suman; Carmen Báez; Wilfrido Redondo; Daniel McClernon; Susan Danehower; E Randall Lanier; Carol Richardson; Amy Keller; Seth Hetherington; Xavier Sáez-Llorens; Octavio Ramilo Journal: J Pediatr Date: 2002-07 Impact factor: 4.406
Authors: J Coplan; K A Contello; C K Cunningham; L B Weiner; T D Dye; L Roberge; M A Wojtowycz; K Kirkwood Journal: Pediatrics Date: 1998-07 Impact factor: 7.124
Authors: C García-Navarro; S Jimenez de Ory; C Velo Higueras; B Zamora; L Prieto; J T Ramos; M L Navarro; L Escosa-García; R Jurado-Barba; Dolores Falcón; David Moreno; M I González-Tomé Journal: Heliyon Date: 2020-04-25
Authors: Anjuli D Wagner; Irene N Njuguna; Jillian Neary; Vincent O Omondi; Verlinda A Otieno; Joseph Babigumira; Elizabeth Maleche-Obimbo; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: BMJ Open Date: 2018-10-03 Impact factor: 2.692